Better Late Than Never: “Breakthrough” Status Aided Sovaldi’s On-Time Approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Although Gilead’s hepatitis C drug picked up the “breakthrough therapy” moniker with just two months left in the NDA review cycle, the designation enabled FDA staff to analyze new VALENCE and PHOTON-1 trial data and still approve sofosbuvir by the PDUFA goal date.